Abstract
Hypoxia has been reported to regulate both stem cell maintenance and differentiation. Wnt signaling is also a key regulator in stem cells. The recent discovery of functional cross-regulation between the Wnt pathway and HIF- 1α/HIF-2α signaling further highlights the complexity of the role of hypoxia in the regulation of stem cells. In this report we reveal that human CML cell lines treated under hypoxic conditions increase the percentage of leukemia stem/initiating-like cells, as judged by surface marker expression, colony forming ability and quiescence. We demonstrate that differential usage of the Kat3 coactivators, CREBBP/Creb Binding Protein (CBP) and EP300 (p300) by catenin, with increased CBP/catenin signaling at the expense of p300/catenin signaling, is mechanistically correlated with the increase in the leukemia stem/initiating-like population. A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions.
Keywords: CBP, CML, ICG-001, hypoxia, leukemia initiating cell, Wnt/catenin inhibitor.
Current Molecular Pharmacology
Title:Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription
Volume: 6
Author(s): Aiko Kida and Michael Kahn
Affiliation:
Keywords: CBP, CML, ICG-001, hypoxia, leukemia initiating cell, Wnt/catenin inhibitor.
Abstract: Hypoxia has been reported to regulate both stem cell maintenance and differentiation. Wnt signaling is also a key regulator in stem cells. The recent discovery of functional cross-regulation between the Wnt pathway and HIF- 1α/HIF-2α signaling further highlights the complexity of the role of hypoxia in the regulation of stem cells. In this report we reveal that human CML cell lines treated under hypoxic conditions increase the percentage of leukemia stem/initiating-like cells, as judged by surface marker expression, colony forming ability and quiescence. We demonstrate that differential usage of the Kat3 coactivators, CREBBP/Creb Binding Protein (CBP) and EP300 (p300) by catenin, with increased CBP/catenin signaling at the expense of p300/catenin signaling, is mechanistically correlated with the increase in the leukemia stem/initiating-like population. A specific small molecule inhibitor of CBP/catenin dependent transcription, ICG-001, can reverse these effects further demonstrating the critical involvement of CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions.
Export Options
About this article
Cite this article as:
Kida Aiko and Kahn Michael, Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/1874467207666140219121219
DOI https://dx.doi.org/10.2174/1874467207666140219121219 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick
Mini-Reviews in Medicinal Chemistry A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued) New Quinoline Based Sulfonamide Derivatives: Cytotoxic and Apoptotic Activity Evaluation Against Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry Integrative Analysis of miRNA-mediated Competing Endogenous RNA Network Reveals the lncRNAs-mRNAs Interaction in Glioblastoma Stem Cell Differentiation
Current Bioinformatics Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry Current Status of Clinical Trials for Glioblastoma
Reviews on Recent Clinical Trials Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists
Current Topics in Medicinal Chemistry Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan’s Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea
Current Cancer Drug Targets Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review
Current Neuropharmacology Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry